Dabictrel approval has been withdrawn even without debut
Hanwha Chemical has voluntarily withdrawn the product approval of ‘Dabictrel(etanercept),’ a Enbrel biosimilar.
Thus, a domestic biosimilar which was approved to be commercialized for the third time has now been disappeared even without a debut in the domestic market.
The Ministry of Food and D...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
